MedPath

Egg Intervention During Pregnancy in Indonesia

Not Applicable
Active, not recruiting
Conditions
Birth Length
Weight Gain
Folate Deficiency
Fatty Acid Deficiency
Parasite Infestation
E. Coli Infection
Mineral Deficiency
Anemia, Iron Deficiency
Birth Weight
Child Development
Interventions
Dietary Supplement: Egg intervention
Registration Number
NCT04694235
Lead Sponsor
SEAMEO Regional Centre for Food and Nutrition
Brief Summary

The study consists of two arms: 1) intervention group using eggs as supplementary food given from 2nd trimester of pregnancy to birth, and 2) observational group of pregnant mothers. it aims to assess the effectiveness of improving dietary quality during pregnancy on the epigenetic and stunting related outcomes (growth and development) in infants, who will be followed up until 24 months old

Detailed Description

The study aims to assess the impact of improving dietary quality during pregnancy on the epigenetic and stunting related outcomes in infants. The open-label intervention study would be conducted alongside the observational study in the same study setting by recruitment of additional number (n=153) of pregnant women. Thus, a total of 653 pregnant women would be enrolled in the study; 153 women would be randomized to intervention arm and 500 to the control arm who would form an observational cohort of women and newborns as described above. The intervention group women will be provided one egg three times per week from recruitment (2nd trimester) until term. The control group women will receive standard intervention in the form of Ante Natal Care from village midwives or Public Health Centre (IFA tablet, calcium tablet, nutrition counselling).

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Female
Target Recruitment
702
Inclusion Criteria
  • Woman is between 16 and 20 weeks of pregnancy based on the date of the first day of her last menstrual period.
  • She is 18-40 years of age.
  • She is planning to remain in the study area over the next 30 months.
  • She is of Sasak ethnicity
Exclusion Criteria
  • She is expecting multiple births.
  • She has a known egg allergy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupEgg interventionThe intervention group women (n=153) will be provided one egg three times per week from recruitment (2nd trimester) until term along with the standard Ante Natal Care.
Primary Outcome Measures
NameTimeMethod
Proportion of children 10-14 months with impaired expressive and receptive language10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess expressive and receptive language among children aged 10 to 14 months

Proportion of children 10-14 months with impaired empathy10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess empathy among children aged 10 to 14 months

Proportion of children 20-24 months with impaired motor development20-24 months of age

INTERGROWTH Neurodevelopment Assessment (INTER-NDA) is used to assess motor development among children aged 20 to 24 months

Proportion of children 20-24 months with impaired social-emotional development20-24 months of age

INTERGROWTH Neurodevelopment Assessment (INTER-NDA) is used to assess social-emotional development among children aged 20 to 24 months

Scores of CDI vocabulary comprehension scale in children 10-12 months10-12 months of age

MacArthur-Bates Communicative Development Inventories (CDI) is used to assess vocabulary comprehension scale among children aged 10 to 12 months

Prevalence of stuntingbirth until 24 months after delivery

Z-score of LAZ \<-2 SD based on WHO 2006

Proportion of children 10-14 months with impaired fine and gross motor skills10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess fine and gross motor skills among children aged 10 to 14 months

Proportion of children 10-14 months with impaired attention10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess attention among children aged 10 to 14 months

Proportion of children 20-24 months with impaired cognition20-24 months of age

INTERGROWTH Neurodevelopment Assessment (INTER-NDA) is used to assess cognition among children aged 20 to 24 months

Proportion of children 20-24 months with impaired language20-24 months of age

INTERGROWTH Neurodevelopment Assessment (INTER-NDA) is used to assess language among children aged 20 to 24 months

Proportion of children 10-14 months with impaired executive function10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess executive function among children aged 10 to 14 months

Proportion of children 10-14 months with impaired problem solving10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess problem solving among children aged 10 to 14 months

Proportion of children 10-14 months with impaired behavior10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess behavior among children aged 10 to 14 months

Scores of CDI vocabulary production scale in children 10-12 months10-12 months of age

MacArthur-Bates Communicative Development Inventories (CDI) is used to assess vocabulary production among children aged 10 to 12 months

Proportion of children 10-14 months with impaired social-emotional reactivity10-14 months of age

Oxford Neurodevelopment Assessment (OX-NDA) is used to assess social-emotional reactivity among children aged 10 to 14 months

Epigenetic state of genes associated with stuntingparents: 72 h after delivery; baby: 72 h after delivery, 24 month

Genome-wide analysis of epigenetic states using the Illumina Infinium Methylation EPIC 850k Bead Chip (EPIC array) will be performed for selected samples from the core cohort. The outcomes will be the epigenetic state of a large number of genes which are associated with child stunting.

Epigenetic markers of birth anthropometry, adult stature, metabolic state, and cognitive abilityparents: 72 h after delivery; baby: 72 h after delivery, 24 month

All samples (newborn, children 24 mo, parents) will be analyzed using Next Generation Bisulphite Amplicon Sequencing (BSAS) from Illumina MiSeq platform in targeted regions of the genome. The outcomes will be profiles of specific epigenetic markers of birth anthropometry, adult stature, metabolic state, and cognitive ability.

Secondary Outcome Measures
NameTimeMethod
Birth length24 hours after birth

All measurements will be taken to the nearest milimeter using standard procedures with SECA stadiometer/infantometer.

Serum zinc concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum zinc

Serum methylmalonic acid concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum methylmalonic acid

Serum CRP concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Subclinical inflammation will be measured by serum CRP in pregnant mothers and children

Serum AGP concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Subclinical inflammation will be measured by serum AGP in pregnant mothers and children

Gut microbiotababy: 1, 6, 24 months of age

Gut microbiota species (EPEC, ETEC, EHEC, EIEC) from fecal will be assesed using qPCR

Intestinal fatty acid binding proteinbaby: 6 months of age

Intestinal fatty acid binding protein from serum will be measured using ELISA

Serum vitamin B12 concentrationMothers: second and third trimester of pregnancy

Nutritional status measured by biochemical assessment to the mothers for their serum vitamin B12

RBC fatty acids concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their RBC fatty acids

Serum betaine concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum betaine

Serum vitamin B2 concentrationMothers: second and third trimester of pregnancy

Nutritional status measured by biochemical assessment to the mothers for their serum vitamin B2

Serum vitamin B6 concentrationMothers: second and third trimester of pregnancy

Nutritional status measured by biochemical assessment to the mothers for their serum vitamin B6

Serum vitamin D concentrationMothers: second and third trimester of pregnancy

Nutritional status measured by biochemical assessment to the mothers for their serum vitamin D

Weight gain during pregnancy2nd trimester (16-20 weeks gestation) and 3rd trimester (28-32 weeks gestation) of pregnancy

All measurements will be taken to the nearest 0.1 kg using standard procedures with SECA weighing machine.

Birth weight24 hours after birth

All measurements will be taken to the nearest 0.1 kg using standard procedures with SECA weighing machine.

Hemoglobin concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their hemoglobin.

Serum ferritin concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum ferritin

Serum transferrin receptor concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum transferrin receptor

Serum retinol concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum retinol

RBC folate concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their RBC folate

Serum choline concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum choline

Serum essential amino acids concentrationMothers: second and third trimester of pregnancy

Nutritional status measured by biochemical assessment to the mothers for their serum essential amino acids

Serum RBP concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum RBP

Serum homocysteine concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum homocysteine

Serum HbA1C concentrationMothers: second and third trimester of pregnancy

Gestational diabetes status will be assesed to the mothers for their serum HbA1C

Fecal α1-antitrypsin (AAT)baby: 1, 6, 24 months of age

Gut inflammation from fecal will be measured by fecal α1-antitrypsin (AAT) using ELISA

Serum hepcidine concentrationMothers: second and third trimester of pregnancy; children: 6 months (+/- 2 weeks) after delivery; breastmilk: 3 and 6 months (+/- 2 weeks) after delivery

Nutritional status measured by biochemical assessment to the mothers and children. Both the pregnant mothers and children will be measured for their serum hepcidine

Bacteria infectionbaby: 1, 6, 24 months of age

Type of bacteria (Salmonella, Shigella) from fecal will be assesed by culture method

Fecal myeloperoxidase (MPO)baby: 1, 6, 24 months of age

Gut inflammation from fecal will be measured by faecal myeloperoxidase (MPO) using ELISA

Soil-transmitted helminths infectionmothers: 3rd trimester (28-32 gestational weeks) of pregnancy; baby: 1, 6, 24 months of age

Fecal parasites from fecal will be assesed by Kato Katz and confirmed by qPCR

Gut microbiomebaby: 1, 6, 24 months of age

Faecal microbiome would be analyzed using 16S RNA sequencing of the V4 region on the Illumina MiSeq and BSAS.

Trial Locations

Locations (1)

Aikmel, Sakra, and Sikur Subdistrict

🇮🇩

Mataram, West Nusa Tenggara, Indonesia

© Copyright 2025. All Rights Reserved by MedPath